Leukotriene Antagonists: Uses, Dosage, Safety In Dermatology

Authoritative facts about Leukotriene Antagonists from DermNet New Zealand, updated January 2026.

Leukotriene antagonists, also known as antileukotrienes, are medications that inhibit the action of leukotrienes, potent inflammatory mediators derived from arachidonic acid via the 5-lipoxygenase pathway. These drugs are primarily approved for asthma and allergic rhinitis but show promise in dermatology for various inflammatory skin conditions.

What are leukotriene antagonists?

Leukotrienes (LTs) contribute to inflammation by promoting bronchoconstriction, mucus secretion, vascular permeability, and immune cell recruitment. In the skin, they exacerbate conditions involving mast cell activation and eosinophil infiltration. Leukotriene antagonists are divided into two main classes:

• Leukotriene receptor antagonists: These block cysteinyl leukotriene receptors (CysLT1 and CysLT2), preventing LT effects. Common agents include montelukast (Singulair®), zafirlukast (Accolate®), and pranlukast (Onon®).
• Leukotriene synthesis inhibitors: These inhibit 5-lipoxygenase, reducing LT production. Zileuton (Zyflo®) is the primary example.

In dermatology, all uses are off-label, supported by case reports, small trials, and pathophysiological rationale rather than large randomized controlled trials (RCTs).

Who gets them and why?

Leukotriene antagonists are considered for patients with inflammatory dermatoses unresponsive to first-line therapies like topical steroids or antihistamines. They target LT-driven pathways in conditions with elevated LT levels, such as increased cysteinyl LTs (LTC4, LTD4, LTE4) in atopic skin.

• Patients with refractory chronic urticaria (CU).
• Those with moderate-to-severe atopic dermatitis (AD), especially extrinsic type.
• Individuals with acne vulgaris seeking antibiotic-sparing options.

Enhanced LT production from basophils, eosinophils, and mast cells in lesional skin justifies their use.

How do they work?

Leukotrienes mediate inflammation via specific receptors. CysLT1 antagonists like montelukast bind with high affinity, blocking vascular permeability, eosinophil chemotaxis, and itch. Zileuton prevents LTB4, LTC4, LTD4, and LTE4 synthesis, reducing overall inflammation.

In AD, intradermal LTD4 induces wheal-and-flare blocked by antagonists. Montelukast reduces eosinophils by 15% and suppresses progenitor proliferation. Zafirlukast inhibits LTD4- and histamine-mediated permeability.

Clinical uses in dermatology

Leukotriene antagonists have been trialed in multiple skin disorders with varying success. Evidence is strongest for urticaria and AD, though larger studies are needed.

Atopic dermatitis

AD involves activated mast cells releasing LTs, with elevated LTC4 in suction blisters and increased basophil releasability. Small RCTs and case series show montelukast reduces sleep disturbance, rash intensity (erythema, edema, excoriation), and eosinophil markers over 4-12 weeks. One study of 16 adults noted reduced eosinophilic cationic protein. Zileuton (600mg QID for 6 weeks) improved objective skin scores (p=0.03) in severe AD.

However, a larger 59-patient trial found no benefit vs. placebo beyond 8 weeks. Best for short-term, steroid-sparing use in extrinsic AD.

Urticaria

In chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIV), LTs contribute via mast cell degranulation. Montelukast and zafirlukast provide additive benefit to antihistamines, especially in aspirin-exacerbated cases due to shunted LT overproduction. Meta-analyses of small RCTs confirm modest efficacy in reducing wheals and itch.

• Chronic inducible urticaria (cold, cholinergic, dermographism).
• Chronic spontaneous urticaria.
• Aspirin-sensitive urticaria.

Acne vulgaris

Emerging data suggest zileuton targets LTB4-mediated inflammation and neutrophil recruitment in acne. Off-label use may prevent antibiotic resistance.

Other conditions

• Granuloma annulare: Case reports of montelukast resolution.
• Bullous pemphigoid: Limited benefit in small series.
• Psoriasis: Few reports; LTs implicated in plaques.
• Pruritus in Sjögren-Larsson syndrome: Symptom relief noted.
• Blistering diseases (pemphigus, epidermolysis bullosa acquisita).

Table 1 summarizes key studies:

Dosage

Montelukast: 10 mg once daily (adults); 4-5 mg daily (children >2 years).
Zafirlukast: 20 mg twice daily (adults); 10 mg BID (children >5 years).
Pranlukast: 450 mg twice daily (adults).
Zileuton: 600 mg four times daily.

Monitor liver function with zafirlukast/zileuton; take zafirlukast 1 hour before/2 hours after meals.

Adverse effects

Generally well-tolerated; common effects (≥5% vs. placebo):

• Headache, abdominal pain, cough, dyspepsia.
• Rare: Churg-Strauss syndrome (monitor asthmatics), neuropsychiatric events (montelukast: mood changes, suicidality – FDA boxed warning).
• Hepatotoxicity (zafirlukast/zileuton).

In dermatology trials, no serious skin-related adverse events reported.

Interactions

• Zileuton: Inhibits CYP3A4; increases theophylline/warfarin levels.
• Zafirlukast: Mild CYP2C9 inhibitor; avoid with erythromycin.
• Montelukast: Minimal interactions.

Contraindications and precautions

• Active liver disease.
• Hypersensitivity.
• Caution in phenylketonuria (montelukast chewables contain aspartame).
• Not for acute attacks.

Conclusion

Leukotriene antagonists offer a valuable adjunct in refractory urticaria and atopic dermatitis, with emerging roles in acne and other dermatoses. Their safety profile supports off-label use, but evidence gaps necessitate more RCTs.

Frequently asked questions

What are leukotriene antagonists used for in skin conditions?

Primarily urticaria and atopic dermatitis; also acne, granuloma annulare, psoriasis.

Are leukotriene antagonists effective for chronic urticaria?

Modest benefit as add-on to antihistamines, per meta-analyses.

Can children use montelukast for atopic dermatitis?

Small studies show short-term efficacy in reducing rash severity.

What are side effects of montelukast?

Headache, GI upset; rare neuropsychiatric effects.

Is zileuton better for acne?

Promising via LTB4 inhibition, potentially antibiotic-sparing.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb